Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Everolimus
Drug ID BADD_D00858
Description Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Indications and Usage Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Marketing Status approved
ATC Code L01EG02; L04AA18
DrugBank ID DB01590
KEGG ID D02714
MeSH ID D000068338
PubChem ID 6442177
TTD Drug ID D0K3QS
NDC Product Code 52076-6247; 62227-019; 68254-6234; 71052-559; 49884-283; 0054-0480; 0078-0566; 0078-0620; 0078-0627; 0378-3096; 0378-3097; 67877-721; 0054-0472; 70377-012; 65129-1324; 71796-012; 0078-0422; 0093-7767; 0093-7768; 49884-119; 51991-821; 63850-0062; 63850-0064; 70377-010; 70377-011; 63850-0059; 67877-718; 0054-0470; 17404-1027; 65727-064; 0078-0567; 51991-824; 63850-0058; 0378-0007; 0378-3098; 0054-0497; 65727-063; 0078-0594; 0078-0628; 49884-158; 0378-0005; 0378-3099; 67877-720; 0054-0471; 52076-6253; 62227-013; 70225-1103; 0078-0415; 0078-0417; 0078-0626; 0054-0482; 52076-6234; 63850-0063; 67877-719; 63850-0061; 0054-0481; 0054-0604; 49884-160; 51991-822; 63850-0060; 0378-0006; 70377-013; 65727-046; 0078-0414; 0093-7766; 49884-125; 49884-127; 49884-128; 49884-159; 51991-823
UNII 9HW64Q8G6G
Synonyms Everolimus | SDZ RAD | RAD, SDZ | SDZ-RAD | 40-O-(2-hydroxyethyl)-rapamycin | RAD 001 | 001, RAD | RAD001 | Certican | Afinitor
Chemical Information
Molecular Formula C53H83NO14
CAS Registry Number 159351-69-6
SMILES CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O) C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysphemia19.19.03.005; 17.02.08.0100.000336%Not Available
Pelvic haematoma21.07.04.001; 24.07.03.0100.000153%Not Available
BK virus infection11.05.05.004--Not Available
Haemorrhage24.07.01.002--Not Available
Varices oesophageal24.10.02.004; 07.15.05.001; 09.01.06.0090.000153%Not Available
Fluid intake reduced14.05.10.0010.001238%Not Available
Pulmonary mass22.02.07.0040.001559%Not Available
Food craving19.09.01.010; 14.03.01.0090.000520%Not Available
Human polyomavirus infection11.05.05.005--Not Available
Chronic hepatic failure09.01.03.009--Not Available
Breast cancer female21.05.01.011; 16.10.01.0040.001590%Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000764%Not Available
Cancer pain16.32.03.0040.000153%Not Available
Incision site pain12.02.05.006; 08.01.08.008--Not Available
Metabolic disorder14.11.01.0010.000413%Not Available
Dyslipidaemia14.08.04.0150.000306%Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.000229%Not Available
Nuchal rigidity17.05.02.006; 15.05.04.0050.000153%Not Available
Dermatitis psoriasiform23.03.14.0040.000153%Not Available
Intestinal mass07.11.01.0100.000229%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000413%Not Available
Perinephric collection20.02.03.014; 12.01.05.003--Not Available
Angiopathy24.03.02.0070.000153%Not Available
Metastases to central nervous system16.22.02.004; 17.02.10.0130.002125%Not Available
Skin toxicity23.03.03.032; 12.03.01.0200.000688%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Abdominal neoplasm16.16.02.002; 07.21.04.0010.000229%Not Available
The 24th Page    First    Pre   24 25 26 27 28    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene